Andrew Potterton

Andrew Potterton is currently the Head of Platform at Adhesion Therapeutics, leading a technology team in the development of a molecular glues design platform. Previously, Andrew served as a Senior Cheminformatics Data Scientist at BenevolentAI, where contributions included leading an internal structural bioinformatics product and presenting at conferences, alongside patent submissions for innovations. As a PhD candidate at UCL, Andrew developed novel protocols for predicting drug-target residence time, significantly enhancing the field of structural bioinformatics. Prior experience includes a PhD placement at Evotec. Andrew holds a PhD in Biological Sciences from UCL and a Bachelor of Science in Biochemistry from the same institution.